Could a lighter MS treatment keep the disease at bay?

NCT ID NCT07757568

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This study tests whether people with relapsing-remitting multiple sclerosis (MS) who have been stable on anti-CD20 therapies can safely switch to a fumarate drug like Tecfidera or Vumerity. The goal is to see if the switch keeps the disease inactive—meaning no relapses, no new brain lesions, and no worsening disability—over two years. Participants must have had no new disease activity for at least two years and be on anti-CD20 therapy for at least one year. The study will also measure a blood biomarker of nerve damage to check for subtle changes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
dimethyl fumarate (Tecfidera) or diroximel fumarate (Vumerity)
What this could lead to
If successful, this could offer a safer, more convenient long-term option for people with stable MS, reducing the need for stronger immunosuppressive therapy.
What could go wrong
This is a small pilot study with only 11 participants, so results may not apply broadly. There is a risk that switching could allow disease activity to return.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS (MS) RELAPSING REMITTING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Colorado, Denver

    Aurora, Colorado, 80045, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.